non-small cell lung cancer

ArriVent takes in $175M from second biotech IPO of the year
Fierce Biotech
Fri, 01/26/24 - 11:17 am
ArriVent Biopharma
IPOs
furmonertinib
China
non-small cell lung cancer
Amgen's request for full approval of Lumakras in lung cancer denied by FDA
Fierce Pharma
Wed, 12/27/23 - 11:02 pm
Amgen
Lumakras
FDA
non-small cell lung cancer
FDA grants priority review for Daiichi Sankyo-Merck’s lung cancer therapy
Pharmaceutical Business Review
Wed, 12/27/23 - 11:00 pm
Daiichi Sankyo
Merkc
patritumab deruxtecan
FDA
non-small cell lung cancer
For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer
Fierce Pharma
Thu, 12/7/23 - 12:00 pm
Merck
Keytruda
non-small cell lung cancer
Lynparza
AstraZeneca
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval
BioSpace
Fri, 12/1/23 - 11:23 am
AbbVie
Teliso-V
antibody-drug conjugate
non-small cell lung cancer
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
Yahoo/Zacks.com
Wed, 11/22/23 - 11:38 am
JNJ
Rybevant
non-small cell lung cancer
AstraZeneca
Tagrisso
5 Cancer Vaccines to Watch in 2024
BioSpace
Mon, 11/20/23 - 10:15 am
Merck
Moderna Therapeutics
melanoma
BioNTech
pancreatic cancer
OSE Immunotherapeutics
Transgene
non-small cell lung cancer
Nykode Therapeutics
cervical cancer
AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop
BioSpace
Tue, 11/14/23 - 10:55 am
AstraZeneca
Imfinzi
clinical trials
non-small cell lung cancer
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
Tue, 10/24/23 - 10:21 am
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
Fierce Biotech
Mon, 10/23/23 - 05:22 pm
ESMO
Daiichi Sankyo
AstraZeneca
Enhertu
patient deaths
clinical trials
non-small cell lung cancer
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
Fri, 10/20/23 - 10:05 am
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
BioSpace
Wed, 10/18/23 - 10:17 am
Genentech
Alecensa
ALK inhibitors
non-small cell lung cancer
ESMO
Merck Pushes Keytruda into Perioperative NSCLC Setting with FDA Approval
BioSpace
Tue, 10/17/23 - 09:36 pm
Merck
Keytruda
non-small cell lung cancer
AZ’s Tagrisso plus chemo get fast FDA review for lung cancer
Pharmaphorum
Mon, 10/16/23 - 10:20 am
AstraZeneca
FDA
Tagrisso
non-small cell lung cancer
EGFR-positive non-small cell lung cancer
Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Fierce Pharma
Tue, 10/10/23 - 10:18 am
Merck
Keytruda
non-small cell lung cancer
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Wed, 10/4/23 - 11:08 am
Amgen
Lumakras
non-small cell lung cancer
FDA
Takeda to Withdraw Oncology Drug Exkivity from U.S. Market
Managed Healthcare Executive
Tue, 10/3/23 - 10:34 am
Takeda
Exkivity
clinical trials
non-small cell lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
Reuters
Thu, 09/28/23 - 12:08 pm
JNJ
non-small cell lung cancer
AstraZeneca
Rybrevant
lazertinib
Tagrisso
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Sun, 09/24/23 - 08:54 pm
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials

Pages